Supplementary Figure S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer

Key Points

• MAIN FINDING: The combination of tifcemalimab and toripalimab was evaluated for effectiveness in advanced lung cancer.
• KEY EVIDENCE: Kaplan-Meier estimates indicated differences in progression-free survival and overall survival rates.
• APPROACH: A phase I/II study was conducted with assessment of immunotherapy responses in previously treated patients.
• SIGNIFICANCE: This research provides insight into potential new treatments for advanced lung cancer patients.